Literature DB >> 2174869

DNA gyrase gyrA mutations in ciprofloxacin-resistant strains of Staphylococcus aureus: close similarity with quinolone resistance mutations in Escherichia coli.

S Sreedharan1, M Oram, B Jensen, L R Peterson, L M Fisher.   

Abstract

The gyrA genes isolated from three ciprofloxacin-resistant clinical isolates of Staphylococcus aureus carried codon 84 (serine----leucine) and/or codon 85 (serine----proline) mutations that were absent in pretreatment susceptible strains. These substitutions occur in a region of the gyrase A protein wherein directly analogous mutations of serine 83----leucine and alanine 84----proline in Escherichia coli confer quinolone resistance. Thus, DNA gyrase A subunit mutations are implicated in resistance to ciprofloxacin in S. aureus.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2174869      PMCID： PMC210851          DOI： 10.1128/jb.172.12.7260-7262.1990

Source DB:  PubMed          Journal:  J Bacteriol        ISSN： 0021-9193            Impact factor:   3.490


  19 in total

1.  Mapping the active site tyrosine of Escherichia coli DNA gyrase.

Authors:  D S Horowitz; J C Wang
Journal:  J Biol Chem       Date:  1987-04-15       Impact factor: 5.157

2.  Cloning and sequencing of the Escherichia coli gyrA gene coding for the A subunit of DNA gyrase.

Authors:  S L Swanberg; J C Wang
Journal:  J Mol Biol       Date:  1987-10-20       Impact factor: 5.469

3.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

4.  DNA gyrase of Staphylococcus aureus and inhibitory effect of quinolones on its activity.

Authors:  M Takahata; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

5.  Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli.

Authors:  H Yoshida; M Bogaki; M Nakamura; S Nakamura
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

6.  Escherichia coli K-12 mutants resistant to nalidixic acid: genetic mapping and dominance studies.

Authors:  M W Hane; T H Wood
Journal:  J Bacteriol       Date:  1969-07       Impact factor: 3.490

7.  Activity of ciprofloxacin against methicillin-resistant Staphylococcus aureus.

Authors:  S M Smith; R H Eng
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

8.  Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity.

Authors:  M Gellert; K Mizuuchi; M H O'Dea; T Itoh; J I Tomizawa
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

9.  The cloning of chromosomal DNA associated with methicillin and other resistances in Staphylococcus aureus.

Authors:  P R Matthews; K C Reed; P R Stewart
Journal:  J Gen Microbiol       Date:  1987-07

10.  Quinolone-resistant mutations of the gyrA gene of Escherichia coli.

Authors:  H Yoshida; T Kojima; J Yamagishi; S Nakamura
Journal:  Mol Gen Genet       Date:  1988-01
View more
  84 in total

1.  Introduction of a norA promoter region mutation into the chromosome of a fluoroquinolone-susceptible strain of Staphylococcus aureus using plasmid integration.

Authors:  G W Kaatz; S M Seo; T J Foster
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

Review 2.  Molecular detection of antimicrobial resistance.

Authors:  A C Fluit; M R Visser; F J Schmitz
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

3.  Detection of gyrA gene mutations associated with ciprofloxacin resistance in methicillin-resistant Staphylococcus aureus: analysis by polymerase chain reaction and automated direct DNA sequencing.

Authors:  J J Goswitz; K E Willard; C E Fasching; L R Peterson
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

4.  Cloning and sequencing of a novel gene (recG) that affects the quinolone susceptibility of Staphylococcus aureus.

Authors:  T Niga; H Yoshida; H Hattori; S Nakamura; H Ito
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

5.  Bacterial natural transformation by highly fragmented and damaged DNA.

Authors:  Søren Overballe-Petersen; Klaus Harms; Ludovic A A Orlando; J Victor Moreno Mayar; Simon Rasmussen; Tais W Dahl; Minik T Rosing; Anthony M Poole; Thomas Sicheritz-Ponten; Søren Brunak; Sabrina Inselmann; Johann de Vries; Wilfried Wackernagel; Oliver G Pybus; Rasmus Nielsen; Pål Jarle Johnsen; Kaare Magne Nielsen; Eske Willerslev
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-18       Impact factor: 11.205

6.  Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations.

Authors:  H E Takiff; L Salazar; C Guerrero; W Philipp; W M Huang; B Kreiswirth; S T Cole; W R Jacobs; A Telenti
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

7.  Small-colony mutants of Staphylococcus aureus allow selection of gyrase-mediated resistance to dual-target fluoroquinolones.

Authors:  Xiao-Su Pan; Penelope J Hamlyn; Raquel Talens-Visconti; Fabiana L Alovero; Ruben H Manzo; L Mark Fisher
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

Review 8.  Mechanisms of resistance to quinolones.

Authors:  E Cambau; L Gutmann
Journal:  Drugs       Date:  1993       Impact factor: 9.546

9.  Quinolone resistance mutations in the GrlB protein of Staphylococcus aureus.

Authors:  M Tanaka; Y Onodera; Y Uchida; K Sato
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

10.  Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.

Authors:  E Y Ng; M Trucksis; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.